Mutant interleukin-2 polypeptides

US10323098B2 · kind B2 · utility

Assignee

• Roche Glycart AG · CH

Inventors

• Oliver Ast · Bassersdorf, CH
• Peter Bruenker · Hittnau, CH
• Anne Freimoser-Grundschober · Bellinzona, CH
• Sylvia Herter · Schlieren, CH
• Thomas Hofer · Zürich, CH
• Ralf Hosse · Baar, CH
• Christian Klein · Iffeldorf, DE
• Ekkehard Moessner · Kreuzlingen, CH
• Valeria G. Nicolini · Küsnacht (ZH), CH
• Pablo Umana · Wollerau, CH

Key dates

• Filing date: Jan 15, 2016
• Grant date: Jun 18, 2019
• Expiry date: Apr 18, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.